Navigation Links
Lupus Research Institute-funded study points to increased risk for lupus in men
Date:9/2/2010

Lupus Research Institute-funded researcher Betty Tsao, PhD, at the University of California Los Angeles has discovered that humansmales in particularwith a variant form of the immune receptor gene "Toll Like Receptor 7 (TLR7)" are at increased risk of developing the autoimmune disease systemic lupus erythematosus (lupus). This breakthrough finding offers renewed hope for developing more targeted treatments.

The powerful finding recently published in the Proceedings of the National Academy of Sciences (PNAS) represents additional strong evidence from human cellsas opposed to mice or other animal cells-that alterations in the TLR7 gene can promote lupus.

Scientists had long been looking for an association between TLR7 gene function and lupus in humans after LRI-funded researcher Silvia Bolland, PhD, reported the discovery in the mouse in 2006.

Validating the Lupus Research Institute's (LRI's) "Human Lupus Biology" initiative to translate mouse findings to human disease, Dr. Tsao has now made the discovery and provided the first evidence that alterations in the TLR7 gene promote lupus in people.

"This is an extremely important scientific and medical advance," said Mark Shlomchik, MD, PhD, professor of laboratory medicine and immunobiology at Yale University. "Before this work, it was known that Toll like receptors 7 and 9 were important in mouse models of lupus, but there was no good, but there was no good evidence for this in people. We only had some evidence that other genes that may work with TLRs were linked to lupus."

"Dr. Tsao's finding that an overactive TLR7 is associated with lupus risk directly implicates the TLR7 gene itself in lupus," Dr. Shlomchik said. "This confirms the mouse data using genetic deficiency and hyperactivity and most importantly identifies TLR7 inhibition as a potential therapy for lupus."

Lupus is a disease of no known cause or cure, although many scientists suspect
'/>"/>

Contact: Liz Bryan
lbryan@spectrumscience.com
202-955-6222 x2526
Lupus Research Institute
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. UCLA study identifies genetic variation linked to lupus in Asian men
2. Genomes of identical twins reveal epigenetic changes that may play role in lupus
3. Lupus Research Institute announces 2009 novel research grants
4. National report shines light on lupus 50-year treatment drought
5. UT Southwestern researchers probe kidney damage, protection in lupus
6. Gene linked to lupus might explain gender difference in disease risk
7. Bochums researchers discover proton diode
8. U-M researchers receive largest single collection of psoriasis DNA samples
9. Why does anxiety target women more? FSU researcher awarded $1.8 million grant to find out
10. Researchers analyze the environmentalists paradox
11. Researchers develop simulation to better understand the effects of sound on marine life
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... A team of researchers from McGill University and ... form of polyethylene ,microbeads, Canadian Journal of ... likely originate from cosmetics, household cleansers, or industrial ... abrasives. Owing to their small size and buoyancy, ... Microplastics are a global contaminant in the ...
(Date:9/18/2014)... spoken language is unique to humans. "The genetic changes ... human evolution to make this possible are largely unknown, ... have," says Wolfgang Enard, Professor of Anthropology and Human ... molecular biological basis of language Enard has now taken ... study, undertaken in collaboration with scientists at several universities, ...
(Date:9/18/2014)... 18, 2014Many Americans across racial and ethnic groups ... impact on their day-to-day life, more so than ... and speech (57% of African-Americans, 49% of non-Hispanic ... When asked which disease or ailment is the ... first among African-Americans followed by AIDS/HIV. Hispanics ...
Breaking Biology News(10 mins):Microplastic pollution discovered in St. Lawrence River sediments 2Language evolution: Quicker on the uptake 2Language evolution: Quicker on the uptake 3Americans rate losing eyesight as having greatest impact on their lives 2Americans rate losing eyesight as having greatest impact on their lives 3
... Di Benedetto and Micaela Caramellino, two doctoral ... received recognition at a student poster event organized ... nano- and micro-sized drug particles. The New Jersey ... was the sponsor. In recent years, ...
... Technology Business Assessment Group will fund four faculty ... identified these one-year projects from a number of ... earlier this spring. Funding for the program ... Property Management, and is generated by royalties from ...
... released today in the online edition of Physiological Genomics finds ... sugary foods. The study offers the first evidence of the ... gene that controls sugar entry into the cells has ... foods high in sugar. The study was conducted ...
Cached Biology News:NJIT doctoral students receive recognition at poster competition 2OSU technologies funded for development 2OSU technologies funded for development 3Genetic variation linked to sugary food 2Genetic variation linked to sugary food 3
(Date:9/18/2014)... the course of a day - car, phone, ... the chemical industry to turn raw materials such ... valuable chemicals that are the ingredients of life,s ... who achieved outstanding progress in driving this energy ... light instead of fossil fuels, has won the ...
(Date:9/18/2014)... CA (PRWEB) September 18, 2014 ... which include Sartorius/Biohit, Socorex, Capp, and AccuPet brand ... volumes of 100 uL or less and are ... and forensic applications. , The micropipette promotions ... quality and economic alternative products to help customers ...
(Date:9/17/2014)... 17, 2014  PDL BioPharma, Inc. (PDL) (NASDAQ: ... firm, Ernst & Young LLP ("EY") that it was resigning ... letter delivered to the Company on September 15, 2014 and ... PDL has issued the following statement in ... number of inquiries on the reason for the resignation of ...
(Date:9/17/2014)... , Sept. 17, 2014 /PRNewswire/ - Oncothyreon Inc. ... intends to offer and sell shares of its Common ... but concurrent underwritten public offerings.  The Series A Convertible ... Oncothyreon Common Stock, provided that conversion will be prohibited ... would beneficially own more than 4.99% of the Common ...
Breaking Biology Technology:Using solar energy to turn raw materials into ingredients for every day life 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 2Major Pipette Distributor Pipette.com Announces Promotions on Sartorius/Biohit, Socorex, Capp, and AccuPet Micropipettes 3PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 2PDL BioPharma Issues Statement on Resignation of Ernst and Young as Corporate Auditors 3Oncothyreon Announces Proposed Public Offerings 2
... to complement VAP advanced cholesterol profileORLANDO, Fla. and ... of the VAP Cholesterol Test, has announced the ... at ACC.09, the American College of Cardiology (ACC) ... more than a dozen new tests, including C-Reactive ...
... January, the industry seems to have taken a deep breath and a step ... cuts that were announced were mostly due to the overall economic difficulty facing ... ... to say the worst is past for health care, it does seem as ...
... Phase 3 programCRANBURY, N.J., March 28 Amicus Therapeutics ... from its ongoing Phase 2 extension study of its ... The results will be presented at the American College ... FL. Phase 2 Extension Study Overview: Twenty-six ...
Cached Biology Technology:Atherotech Unveils New Cardiometabolic Test Panels 2Atherotech Unveils New Cardiometabolic Test Panels 3The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: Febraury 2009 Employment Outlook for Biotech/Pharma/Health 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 2Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 3Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 4Amicus Therapeutics Presents Positive Results From Phase 2 Extension Study of Amigal(TM) for Fabry Disease at ACMG 2009 Annual Meeting 5
Request Info...
Request Info...
Request Info...
... Versatile state of the Art GLP ... to dual 38,000 L fermentation. ... to production. Aseptic operation capable ... Fed-Batch, and Continuous Modes. Hosts ...
Biology Products: